{"id":935241,"date":"2026-02-09T09:13:53","date_gmt":"2026-02-09T14:13:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/"},"modified":"2026-02-09T09:13:53","modified_gmt":"2026-02-09T14:13:53","slug":"palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/","title":{"rendered":"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET<\/i>\n      <\/p>\n<p align=\"center\">\n        <i>Access the webcast <\/i><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k70oEUiQEulehY482TYnyljtfYkszTDB7xcTmCdHDytw_Oyvmulc4ebMBZnNBL8nPSJWiykIkqA_SAj4SixexhCymvauoQ4FWeqqk5J4i9VMpFYNNekaNVlUkQt-O5Rpo1lnENORFnxY2fal8yxjCUYBj_JDk87aCkLbCjL4bUwBGMCAIdKBGyU4DnLd0YHmPhXyE6fYXRYYcVd8KJxXpOb0FKUptLQKQfT6o6G0Tgg=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <i>here<\/i><br \/>\n        <\/a>\n      <\/p>\n<p align=\"justify\">\n        <strong>Carlsbad, CA, Feb.  09, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong>Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UNDz-cLhKPR2PEw2nkMhyOOV_btFrjrz5Y3t7IrHpRB0PYcDxYGf7Lk4ol5FtZJydKSEFIGmNwTJbaXh83PpwxLWGTlmBsjZKh8b_t_qFq06rRaAYR7N-HtsZTd4ZdA_EI1ASy2zhGRW37ap2l40IyVhtCVQy5R8jRogquOid3GrpM8qEMw6hmHwf2tvPR044w78pc-V3cnyBuhVFu1UBiOdcmM7-3OFLfyDfeJ9eXo=\" rel=\"nofollow\" target=\"_blank\">JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer<\/a>, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET.<\/p>\n<p align=\"justify\">The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets and therapeutic approaches in immunology. In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.<\/p>\n<p align=\"justify\">A <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KEoiGiRfyOsf7r58gJjC5L5hnBnfnCs8Yw7hafTf7MSEjfQSYnM-puQhhv0Vp6CjOVHL1BIio4C8HfK89l8ChcHqqxeLSEXmgaQ4j3E4MG8Vi0k5-d_DHLV7ohOW9t7HDxi7lEidk2N5NTd4ZTUKOxy7HbEXEX_RQjLP3dC3GuGCW7h5uBsM1mhFZby2Jz4GuJvUnmKZa1I_eqsxdrV8GwrVZq5nIoM7i-8avAjJhJk=\" rel=\"nofollow\" target=\"_blank\">live webcast<\/a> of the presentation will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BA9U5ui_yW7JBmVS2ifuRV5r0z4bdfj6DUuhs96o0m67sopPuJxG_69V2oy4uYg4lYl0eY1lXi-t3QSJzs161A==\" rel=\"nofollow\" target=\"_blank\">Events<\/a> page in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q_-jpgV-NIO6olG9XVHuiddMPc63Y4t0EynOepZNQvD2IxaGwNntuA8b-GDbuVcYzxZu4Pee4k9tEhewIeNSc2Kh9VOqsT2bsZYmNnf56cA=\" rel=\"nofollow\" target=\"_blank\">Investors<\/a> section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q152Kx-SbduCkDtehgyhnlGIMmMLEQxxZjXtwbrQXC3NSufDYlYAxCmIPbir-sTGhfUfNz15RtArL8wtt-vT75bptlTYdZh3EsZqZW54N2E=\" rel=\"nofollow\" target=\"_blank\">palisadebio.com<\/a>. A replay will be available following the live event and will be archived for a limited time.<\/p>\n<p align=\"justify\">\n        <b>About PALI-2108<\/b><\/p>\n<p>PALI-2108 is a once-daily, oral prodrug designed for targeted delivery of PDE4 inhibition to the terminal ileum and colon through local bacterial bioactivation. The prodrug is pharmacologically inactive until it reaches the lower intestine, where bacterial enzymes convert it into the active PDE4 inhibitor at sites of inflammation and fibrosis. This targeted activation strategy prevents absorption in the upper gut, enables sustained local exposure with controlled systemic distribution, and is engineered to reduce peak plasma levels, thereby improving the overall therapeutic index and reducing tolerability limitations such as diarrhea, nausea and headache that have constrained systemic PDE4 inhibitors.<\/p>\n<p align=\"justify\">\n        <b>About Palisade Bio<\/b>\n      <\/p>\n<p align=\"justify\">Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d) is a clinical-stage biopharmaceutical company advancing a next generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.<\/p>\n<p align=\"justify\">The Company\u2019s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.<\/p>\n<p align=\"justify\">Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is completing early studies in FSCD to further characterize PALI-2108\u2019s safety, pharmacology and potential therapeutic benefit across inflammatory bowel disease indications. For more information, please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kwCrjlWYABjVOkzjAWnmk7nckk6Z-2thDtZebjBUe2u5dnUlIq8f7lfDWCUIXRZHM2hCMz8onWYucj1lgMhNR7oEfba5Qepmgyk-rXbjFIg=\" rel=\"nofollow\" target=\"_blank\">www.palisadebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: statements regarding the timing and results of clinical trials, the potential mechanisms of action and therapeutic benefits of PALI-2108, and plans for regulatory submissions. These forward-looking statements are based on the Company\u2019s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company\u2019s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company\u2019s clinical trials; the Company\u2019s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, activity, dosing or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company\u2019s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 24, 2025, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.<\/p>\n<p align=\"justify\">\n        <b>Investor Relations Contact<\/b>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC<br \/>Jenene Thomas<br \/>908-824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TMcZND7NBs740Mf95wJ09pfV0fO5Pcie9c_Totx5iclVcv06q6NExzUWHhILZ8xWf5qKgQD2ljRbgJfFQ_dCXO-UdbaC6IY5DxteI6SeYse58ZXxCXGg3pcwD6vmnuztOZ5tiHUbD54ySBlxJdDj6aOG-e0AE9UJG3-ioQ1bF7GZgD4uW3ZD4z1sdjnllxOILbzyrIUIiRpBavzYhYljrA==\" rel=\"nofollow\" target=\"_blank\">PALI@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTg1ODIxMjQtYjFjNi00ODVhLThmMDktYjQ5ODQ1ODAzM2U2LTUwMDEwOTEyMS0yMDI2LTAyLTA5LWVu\/tiny\/Palisade-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that\u00a0JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET. The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-935241","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that\u00a0JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET. The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets &hellip; Continue reading &quot;Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T14:13:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium\",\"datePublished\":\"2026-02-09T14:13:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/\"},\"wordCount\":857,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/\",\"name\":\"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==\",\"datePublished\":\"2026-02-09T14:13:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - Market Newsdesk","og_description":"Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) &#8212; Palisade Bio, Inc. (Nasdaq: PALI) (\u201cPalisade\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that\u00a0JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Officer, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET. The symposium will host analyst-led fireside chats and discussions with public and private companies exploring emerging targets &hellip; Continue reading \"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-09T14:13:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium","datePublished":"2026-02-09T14:13:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/"},"wordCount":857,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/","name":"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==","datePublished":"2026-02-09T14:13:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1MDk0MiM3NDE1MzY0IzUwMDEwOTEyMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-to-participate-in-the-piper-sandler-virtual-novel-targets-in-immunology-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=935241"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/935241\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=935241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=935241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=935241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}